AVNS vs BDX
AVNS: Avanos Medical provides specialized medical device solutions for enteral nutrition and non-opioid pain management to improve patient recovery outcomes. BDX: A global medical technology leader providing essential healthcare supplies, diagnostic systems, and biosciences research tools to improve patient outcomes.
Side-by-side fundamentals
| Metric | AVNS | BDX | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $24.99 | $182.75 | |
| Market cap | $1.2B | $49.8B | |
| P/E as of 2026-10-08 | n/a | 55.14 | |
| Net margin FY2025, SEC XBRL | -10.4% | +7.7% | BDX higher |
| Gross margin FY2025, SEC XBRL | +50.5% | n/a | |
| Operating margin FY2025, SEC XBRL | -8.8% | +11.8% | BDX higher |
| ROE FY2025, SEC XBRL | -9.4% | +6.6% | BDX higher |
| ROA FY2025, SEC XBRL | -6.8% | +3.0% | BDX higher |
| Debt / equity as of 2026-09-03 | 0.13 | 0.69 | AVNS lower |
| Revenue growth (YoY) as of 2026-09-03 | +3.9% | -2.6% | AVNS higher |
| Revenue CAGR (3y) SEC XBRL | +0.8% | +5.0% | BDX higher |
| Dividend yield as of 2026-09-03 | n/a | +2.3% | |
| Dividend streak (yrs) SEC XBRL | 0 | 13 | BDX higher |
| Beta as of 2026-09-03 | 0.73 | 0.45 | |
| 1-year return as of 2026-10-08 close | +119.2% | +19.9% | AVNS higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.